Exicure Inc (XCUR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Region:North America

Author(s):

Product Code:GDPH375392D

Download Sample Report download
Buy the Full ReportStarting from $250
Published on

October 2018

Total pages

43

Table of Content

Download Sample Report download
Buy the Full ReportStarting from $250

About the Report

About the Report

Summary

Exicure Inc (Exicure), formerly AuraSense Therapeutics LLC is a biotechnology company that discovers, develops, and commercializes immunomodulatory and gene silencing drugs based on 3-dimensional spherical nucleic acid constructs. The company's technology portfolio includes SNA gene regulation platform and genetic analysis tools. Its pipeline spans SNA based therapeutics for the treatment of psoriasis, fibrosis, diabetic ulcers, bladder cancer, and inflammation. Exicure SNA's are also used as immunotherapeutic agents for the treatment of cancer and other infectious diseases. The company works in collaboration with various pharmaceutical and biotechnology companies for exploring its SNA platform application against multiple diseases. Exicure is headquartered in Skokie, Illinois, the US.

Exicure Inc (XCUR)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Products

Products

Exicure Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Table of Contents

Table of Contents

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Exicure Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Exicure Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Exicure Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Exicure Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Exicure Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Exicure Inc, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Exicure Secures Venture Funding 12

Exicure Raises USD14.8 Million Financing 13

AuraSense Therapeutics Raises USD4.4 Million in Extended Series C Financing 14

AuraSense Therapeutics Raises USD13.6 Million in Series C Financing 15

AuraSense Therapeutics Raises Funds Through Extended Series B Financing 16

Private Equity 17

Exicure to Raise USD22 Million in Private Placement of Shares 17

Partnerships 19

Exicure Enters into Agreement with Ohio State University 19

Merger 20

Exicure and Max-1 Acquisition Merges in Reverse Merger Transaction 20

Licensing Agreements 21

Purdue Pharma Enters into Licensing Agreement with Exicure 21

Exicure Enters into Licensing Agreement with Northwestern University 22

Exicure Enters into Licensing Agreement with Northwestern University for SNA Technology 23

Equity Offering 24

Exicure Plans to Raise up to USD119.1 Million in Private Placement of Shares 24

Exicure Raises Additional USD11.2 Million in Private Placement of Shares 25

Exicure Raises USD20 Million in Private Placement 26

Exicure Inc-Key Competitors 27

Exicure Inc-Key Employees 28

Exicure Inc-Locations And Subsidiaries 29

Head Office 29

Recent Developments 30

Financial Announcements 30

Aug 06, 2018: Exicure provides update on corporate progress and second quarter 2018 financial results 30

May 15, 2018: Exicure Announces First Quarter 2018 Financial Results 32

Mar 09, 2018: Exicure Reports Full Year 2017 Financial Results And Corporate Progress 34

Nov 14, 2017: Exicure Reports Third Quarter 2017 Financial Results and Provides Business Update 36

Corporate Communications 38

Apr 20, 2018: Exicure Appoints Matthias Schroff As Chief Operating Officer 38

Clinical Trials 39

Oct 02, 2018: Exicure presents first data demonstrating both oral Delivery and liver Delivery of Spherical Nucleic Acid constructs in animal models 39

Jun 14, 2018: Exicure to Present Data at the Cure Spinal Muscular Atrophy Annual Conference in Dallas 40

Other Significant Developments 41

May 23, 2018: Exicure To Begin Trading on United States OTCQB Under the Symbol XCUR 41

May 27, 2017: Investors flock to exicure s IPO-Luye Pharma s strategy of investment in novel biopharmaceuticals receives optimistic outlook 42

Appendix 43

Methodology 43

About GlobalData 43

Contact Us 43

Disclaimer 43


List of Figure

List of Figures

Exicure Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Exicure Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Exicure Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Exicure Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Exicure Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Exicure Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Exicure Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Exicure Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List of Table

List of Tables

Exicure Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Exicure Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Exicure Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Exicure Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Exicure Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Exicure Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Exicure Secures Venture Funding 12

Exicure Raises USD14.8 Million Financing 13

AuraSense Therapeutics Raises USD4.4 Million in Extended Series C Financing 14

AuraSense Therapeutics Raises USD13.6 Million in Series C Financing 15

AuraSense Therapeutics Raises Funds Through Extended Series B Financing 16

Exicure to Raise USD22 Million in Private Placement of Shares 17

Exicure Enters into Agreement with Ohio State University 19

Exicure and Max-1 Acquisition Merges in Reverse Merger Transaction 20

Purdue Pharma Enters into Licensing Agreement with Exicure 21

Exicure Enters into Licensing Agreement with Northwestern University 22

Exicure Enters into Licensing Agreement with Northwestern University for SNA Technology 23

Exicure Plans to Raise up to USD119.1 Million in Private Placement of Shares 24

Exicure Raises Additional USD11.2 Million in Private Placement of Shares 25

Exicure Raises USD20 Million in Private Placement 26

Exicure Inc, Key Competitors 27

Exicure Inc, Key Employees 28

You can also purchase parts of this report.
Do you want to check out a section wise price list?
Get Price Break-up

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022